RS52216B - Jedinjenja i metode za modulaciju fxr-a - Google Patents

Jedinjenja i metode za modulaciju fxr-a

Info

Publication number
RS52216B
RS52216B RS20120099A RSP20120099A RS52216B RS 52216 B RS52216 B RS 52216B RS 20120099 A RS20120099 A RS 20120099A RS P20120099 A RSP20120099 A RS P20120099A RS 52216 B RS52216 B RS 52216B
Authority
RS
Serbia
Prior art keywords
phenyl
cyclopropyl
dichloro
isoxazol
methyl
Prior art date
Application number
RS20120099A
Other languages
English (en)
Serbian (sr)
Inventor
Michael James Genin
Melendo Ana Belen Bueno
Peter Rudolph Manninen
Alan M. Warshawsky
Francisco Javier Agejas-Chicharro
Original Assignee
Eli Lilly & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly & Company filed Critical Eli Lilly & Company
Publication of RS52216B publication Critical patent/RS52216B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
RS20120099A 2007-07-16 2008-07-11 Jedinjenja i metode za modulaciju fxr-a RS52216B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94997407P 2007-07-16 2007-07-16
PCT/US2008/069719 WO2009012125A1 (en) 2007-07-16 2008-07-11 Compounds and methods for modulating fxr

Publications (1)

Publication Number Publication Date
RS52216B true RS52216B (sr) 2012-10-31

Family

ID=39855171

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120099A RS52216B (sr) 2007-07-16 2008-07-11 Jedinjenja i metode za modulaciju fxr-a

Country Status (31)

Country Link
US (1) US8153624B2 (cg-RX-API-DMAC7.html)
EP (1) EP2178851B1 (cg-RX-API-DMAC7.html)
JP (1) JP5373788B2 (cg-RX-API-DMAC7.html)
KR (1) KR101157334B1 (cg-RX-API-DMAC7.html)
CN (1) CN101743232B (cg-RX-API-DMAC7.html)
AR (1) AR067540A1 (cg-RX-API-DMAC7.html)
AT (1) ATE539065T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008276236B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0814571A2 (cg-RX-API-DMAC7.html)
CA (1) CA2693406C (cg-RX-API-DMAC7.html)
CL (1) CL2008002051A1 (cg-RX-API-DMAC7.html)
CO (1) CO6270212A2 (cg-RX-API-DMAC7.html)
CY (1) CY1112298T1 (cg-RX-API-DMAC7.html)
DK (1) DK2178851T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2010000018A (cg-RX-API-DMAC7.html)
EA (1) EA016475B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP109879A (cg-RX-API-DMAC7.html)
ES (1) ES2376176T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120048T1 (cg-RX-API-DMAC7.html)
IL (1) IL202234A0 (cg-RX-API-DMAC7.html)
MA (1) MA31683B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010000502A (cg-RX-API-DMAC7.html)
PE (1) PE20090809A1 (cg-RX-API-DMAC7.html)
PL (1) PL2178851T3 (cg-RX-API-DMAC7.html)
PT (1) PT2178851E (cg-RX-API-DMAC7.html)
RS (1) RS52216B (cg-RX-API-DMAC7.html)
SI (1) SI2178851T1 (cg-RX-API-DMAC7.html)
SV (1) SV2010003458A (cg-RX-API-DMAC7.html)
TN (1) TN2010000028A1 (cg-RX-API-DMAC7.html)
TW (1) TW200906823A (cg-RX-API-DMAC7.html)
WO (1) WO2009012125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2014500319A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
WO2012087520A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
KR102350357B1 (ko) * 2013-11-05 2022-01-14 노파르티스 아게 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법
CN104045635A (zh) * 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CA2981503C (en) 2015-03-31 2023-09-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CR20170456A (es) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
US11419878B2 (en) 2016-03-28 2022-08-23 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) * 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
MA55632A (fr) * 2016-08-23 2022-02-16 Ardelyx Inc Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
RU2019110779A (ru) * 2016-09-14 2020-10-15 Новартис Аг Новые схемы введения агонистов fxr
MX2019003790A (es) * 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
MX394743B (es) * 2017-04-12 2025-03-04 Il Dong Pharma Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CN109320509B (zh) * 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
JP7271513B2 (ja) 2017-09-14 2023-05-11 アルデリックス， インコーポレイテッド 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬
CN111278817B (zh) 2017-11-01 2023-05-16 百时美施贵宝公司 作为法尼醇x受体调节剂的多环化合物
JP7264906B2 (ja) * 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
CA3081424A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
CN111630051B (zh) 2017-11-01 2023-12-26 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃螺环化合物
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US11667629B2 (en) 2017-12-22 2023-06-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Isoxazole derivative, preparation method therefor, and use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CN110452235B (zh) * 2018-05-08 2023-02-17 中国科学院上海药物研究所 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
EP3844156A4 (en) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF HEPATIC DISORDERS
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
CN113677659B (zh) 2019-02-15 2024-09-06 百时美施贵宝公司 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
KR20210129684A (ko) 2019-02-15 2021-10-28 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물
CN113677666A (zh) 2019-02-15 2021-11-19 百时美施贵宝公司 作为类法尼醇x受体调节剂的经取代的双环化合物
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
KR20250076664A (ko) 2019-04-19 2025-05-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Fxr 소분자 작용제 및 이의 제조 방법과 용도
WO2020231917A1 (en) * 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
SG11202113155XA (en) 2019-05-30 2021-12-30 Intercept Pharmaceuticals Inc Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
EP3999101A1 (en) 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
KR20220098168A (ko) * 2019-11-08 2022-07-11 테른스 파마슈티칼스, 인크. 간 장애의 치료
WO2021108974A1 (en) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
US20210379043A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CA3193057A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
EP4210705A4 (en) * 2020-09-11 2024-11-13 Terns Pharmaceuticals, Inc. SOLID DISPERSION FORMULATIONS OF A FXR AGONIST
AU2021359895A1 (en) * 2020-10-15 2023-06-15 Eli Lilly And Company Polymorphs of an fxr agonist
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
CN119013027A (zh) 2021-11-11 2024-11-22 拓臻制药公司 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
WO2023220404A1 (en) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis
CN115850152B (zh) * 2022-12-20 2025-10-31 河北鼎泰制药有限公司 一种杂质A-7-imp3的制备方法及其用途
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
BR0312503A (pt) 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
JP2006515838A (ja) * 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
CA2640476A1 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
BRPI0712262A2 (pt) 2006-05-24 2012-07-10 Lilly Co Eli agonistas de fxr
US8106077B2 (en) 2006-05-24 2012-01-31 Eli Lilly And Company Compounds and methods for modulating FXR

Also Published As

Publication number Publication date
MX2010000502A (es) 2010-03-26
CA2693406A1 (en) 2009-01-22
SV2010003458A (es) 2011-01-10
ES2376176T3 (es) 2012-03-09
PL2178851T3 (pl) 2012-05-31
US20100152166A1 (en) 2010-06-17
KR101157334B1 (ko) 2012-06-15
ECSP109879A (es) 2010-02-26
AU2008276236B2 (en) 2013-03-14
PE20090809A1 (es) 2009-06-27
TW200906823A (en) 2009-02-16
EA016475B1 (ru) 2012-05-30
EP2178851A1 (en) 2010-04-28
HRP20120048T1 (hr) 2012-02-29
EP2178851B1 (en) 2011-12-28
WO2009012125A1 (en) 2009-01-22
CA2693406C (en) 2014-04-29
IL202234A0 (en) 2010-06-16
TN2010000028A1 (en) 2011-09-26
AU2008276236A1 (en) 2009-01-22
JP2010533722A (ja) 2010-10-28
ATE539065T1 (de) 2012-01-15
JP5373788B2 (ja) 2013-12-18
EA201070148A1 (ru) 2010-06-30
CY1112298T1 (el) 2015-12-09
CN101743232A (zh) 2010-06-16
CN101743232B (zh) 2013-03-06
KR20100020999A (ko) 2010-02-23
DOP2010000018A (es) 2010-01-31
CL2008002051A1 (es) 2009-05-29
PT2178851E (pt) 2012-02-27
MA31683B1 (fr) 2010-09-01
SI2178851T1 (sl) 2012-02-29
DK2178851T3 (da) 2012-02-06
BRPI0814571A2 (pt) 2015-01-06
CO6270212A2 (es) 2011-04-20
AR067540A1 (es) 2009-10-14
US8153624B2 (en) 2012-04-10

Similar Documents

Publication Publication Date Title
RS52216B (sr) Jedinjenja i metode za modulaciju fxr-a
AU2007291514B2 (en) Heterocyclic FXR binding compounds
US8106077B2 (en) Compounds and methods for modulating FXR
ES2255294T3 (es) Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
US8193192B2 (en) Heterocyclic FXR binding compounds
EP2128158A1 (en) Heterocyclic cyclopropyl-substituted FXR binding compounds
EA015632B1 (ru) Агонисты fxr
CN108064223A (zh) 含羟基的fxr(nr1h4)调节化合物
PT1828172E (pt) Derivados de pirrol com a actividade antagonista de receptor crth2
CN101287722A (zh) 作为代谢型谷氨酸受体拮抗剂的取代的哌嗪
TW200800150A (en) Compounds with medicinal effects due to interaction with the glucocorticoid receptor
ES2342222T3 (es) Agonistas de fxr.
WO2005080385A1 (ja) インダノール誘導体
HU211690A9 (hu) Az átmeneti oltalom az 1—18. igénypontokra vonatkozik.
HK1146664B (en) P38 inhibitors and methods of use thereof
HK1146664A1 (zh) P38抑制剂及它们的使用方法